SkyePharma closes open offer
This article was originally published in Scrip
SkyePharmahas announced the close of its open offer of 14,017,807 new ordinary shares at a price of 150 pence each. Valid applications were received from qualifying shareholders for 8,908,783 consolidated new ordinary shares, representing around 64% of the amount of shares on offer. The company raised £18.4 million in the offer and the remaining shares have been conditionally allotted to placees.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.